FDA Authorizes OraSure’s COVID-19 Rapid Tests For OTC Single-Use
The FDA has amended OraSure Technologies Inc’s (NASDAQ:OSUR) Emergency Use Authorization (EUA) for its InteliSwab COVID-19 rapid tests to only require…
White House Advisor ZIents Says Quidel, OraSure Are Further/More Rapidly Expanding Production Of Their Tests To Get More Capacity Of The Market
https://twitter.com/davidalim/status/1445827538547138564
OraSure Wins $109M Contract To Increase COVID-19 Test Manufacturing Capacity
OraSure Technologies Inc (NASDAQ:OSUR) has secured a $109 million contract from the U.S. Department of Defense to build additional manufacturing capacity…
FDA Establishes Additional Conditions Of Emergency Use Nod For COVID-19 Tests For Viral Mutations
The FDA has issued a letter to establish additional conditions of Emergency Use Authorizations (EUAs) manufacturers of COVID-19 tests.
OraSure Technologies Reports Will Receive U p To $13.6M From Biomedical Advanced Research Development Authority To Support InteliSwab COVID-19 Rapid Test 510(k) Clearance, Clinical Lab Improvement Amendments Waiver
OraSure Technologies, Inc. (NASDAQ:OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that the Biomedical Advanced Research Development Authority
Raymond James Downgrades OraSure Technologies to Market Perform
Raymond James analyst Andrew Cooper downgrades OraSure Technologies (NASDAQ:OSUR) from Outperform to Market Perform.